NHLBI Archives
PheWAS reveals post-COVID-19 diagnoses
Sep. 8, 2022—Using a high-throughput informatics technique and electronic health records, Vanderbilt researchers found that COVID-19 survivors had an increased risk for more than 40 new diagnoses.
A new mechanism for lupus
Aug. 30, 2022—Vanderbilt researchers describe a new mechanism for the most common form of lupus and suggest a new treatment approach to this autoimmune disease.
Blood cancer progression
Aug. 29, 2022—Vanderbilt researchers used single-cell technologies to explore the accumulation of mutations during blood cancer progression, which could help identify strategies for preventing leukemia before it occurs.
Rheumatoid arthritis and heart disease: a common path
Aug. 25, 2022—An increase in certain antibodies in patients with rheumatoid arthritis can serve as a predictive biomarker for cardiovascular disease, Vanderbilt researchers have discovered.
Researchers discover how salt increases blood pressure
Aug. 17, 2022—A Vanderbilt research team has discovered that activation of a certain protein complex involved in the inflammatory response in immune cells contributes to salt-sensitive hypertension.
Preempting sudden cardiac death
Jul. 7, 2022—A technique to characterize all variants in genes associated with arrhythmia could improve the ability to identify and preemptively treat individuals at risk for sudden cardiac death.
BMI genetics influence heart function
Jun. 16, 2022—Vanderbilt researchers have discovered that a genetic predisposition to elevated body mass index increases the risk of diastolic dysfunction — a cardiac condition that can lead to heart failure.
Diabetes, cardiovascular drug targets
May. 24, 2022—Targeting receptors of the inflammatory lipid signaling molecule PGE2 may offer a new way to tackle both Type 2 diabetes and cardiovascular disease, Vanderbilt researchers have discovered.
A clue to an adverse drug event in children
May. 19, 2022—Considering metabolic (CYP2D6) enzyme activity score and patient age may aid in determining an individual’s risk for an adverse event with administration of the anti-arrhythmic drug propafenone.
Gene variants and transplant drug dose
May. 9, 2022—Genotyping multiple enzymes that metabolize the immunosuppressive drug tacrolimus — common used for lung transplant recipients — is important for correct dosing of the drug, Vanderbilt researchers found.
VUMC team discovers how bacterial pathogen survives without water
May. 5, 2022—Vanderbilt researchers are studying a bacterial pathogen that can survive on hospital surfaces — without water — for months, an ability that has helped it become a leading cause of hospital-acquired infections.
Gene network linked to Type 2 diabetes
May. 5, 2022—Vanderbilt researchers used a novel analytical approach to identify a network of genes associated with Type 2 diabetes, including 31 genes that had not previously been associated with the disease.
